For research use only. Not for therapeutic Use.
ARV-110 (CAT: I022481) is a small molecule drug that falls under the class of androgen receptor degraders. It is being developed as a potential treatment for prostate cancer, particularly in cases that have become resistant to conventional anti-androgen therapies. ARV-110 works by binding to the androgen receptor (AR) and inducing its degradation, leading to a reduction in AR levels and inhibition of AR signaling. By targeting the androgen receptor for degradation, ARV-110 aims to overcome resistance mechanisms that often arise during prostate cancer treatment. It is administered orally and has shown promising results in preclinical and early clinical studies, demonstrating efficacy in reducing tumor growth and potentially improving patient outcomes.
| Catalog Number | I022481 |
| CAS Number | 2222112-77-6 |
| Synonyms | ARV-110; ARV 110; ARV110; Bavdegalutamide |
| Molecular Formula | C41H43ClFN9O6 |
| Purity | 98% |
| Solubility | To be determined |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | N-((1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl)-6-(4-((4-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3-carboxamide |
| InChI | InChI=1S/C41H43ClFN9O6/c42-31-19-28(4-1-25(31)22-44)58-27-5-2-26(3-6-27)45-38(54)33-7-9-36(48-47-33)51-13-11-24(12-14-51)23-49-15-17-50(18-16-49)35-21-30-29(20-32(35)43)40(56)52(41(30)57)34-8-10-37(53)46-39(34)55/h1,4,7,9,19-21,24,26-27,34H,2-3,5-6,8,10-18,23H2,(H,45,54)(H,46,53,55)/t26-,27-,34? |
| InChIKey | CLCTZVRHDOAUGJ-SYVGMNBRSA-N |
| SMILES | ClC1=CC(O[C@H]2CC[C@@H](CC2)NC(C3=CC=C(N=N3)N4CCC(CC4)CN5CCN(CC5)C6=CC(C(N7C8CCC(NC8=O)=O)=O)=C(C=C6F)C7=O)=O)=CC=C1C#N |
| Reference | 1: Zeng S, Huang W, Zheng X, Liyan Cheng, Zhang Z, Wang J, Shen Z. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. Eur J Med Chem. 2021 Jan 15;210:112981. doi: 10.1016/j.ejmech.2020.112981. Epub 2020 Oct 31. PMID: 33160761. |
